A Pilot Trial for Midlife and Older Adults: Sleep and Circadian Treatment Plus Memory Support and Boosters
Abstract
Objectives: Sleep and circadian problems are prevalent among midlife and older adults. Unfortunately, treatments for these problems are limited by poor memory for treatment.
Methods: We conducted a pilot trial of the Transdiagnostic Intervention for Sleep and Circadian Dysfunction paired with the Memory Support Intervention (TSC+MSI) for midlife and older adults with sleep and circadian problems (N = 26) (preregistration NCT04373538). After treatment, patients were offered optional booster messages. Aims were to (1) test change in clinical outcomes after TSC+MSI, (2) assess perceptions of TSC+MSI, and (3) evaluate patient engagement, preferences, and preliminary outcomes of booster messages.
Results: Following TSC+MSI, patients significantly improved on sleep disruption, sleep-related impairment, functional impairment, and select sleep diary outcomes. Therapist use of memory support strategies moderated improvements in sleep-related and overall impairment. TSC+MSI was perceived as acceptable by patients and feasible by therapists. Most patients opted in to the boosters. Sleep-related impairment significantly improved from pre-booster to post-booster.
Conclusions: Following TSC+MSI and boosters, improvements were observed in clinical outcomes, and signals supported feasibility and acceptability.
Clinical implications: Although comparisons with control conditions and larger samples are needed, TSC+MSI and booster messages may improve sleep and circadian and related outcomes…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 26 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.